Chest
Original ResearchCOPDPlasma Pro-Adrenomedullin But Not Plasma Pro-Endothelin Predicts Survival in Exacerbations of COPD
Section snippets
Setting and Study Population
This prospective cohort study took advantage of baseline data from 167 patients with acute exacerbations of COPD, who were admitted to the emergency department of the University Hospital Basel and were included in a prospective, randomized trial.8 A predefined secondary end point was the assessment of further biomarkers in COPD patients.38, 39
The diagnosis of COPD was based on clinical history, physical examination findings, and spirometric criteria according to the Global Initiative for
Results
The detailed baseline characteristics of the 167 patients are presented in Table 1. Overall, 116 patients (69.5%) had relevant comorbidities. Sputum cultures grew bacterial pathogens in 65 cases (38.9%). Echocardiography results were available for 123 patients (73.7%). A total of 38 patients (22.8.%) demonstrated clinically relevant pulmonary arterial hypertension.45 In 12 cases (7.2%), echocardiography showed decreased left ventricular ejection fraction (ejection fraction, ≤ 40%).
The median
Discussion
In this investigation, we have examined the predictive value of plasma proET-1 and proADM levels on survival in patients with acute exacerbations of COPD requiring hospitalization. We have reported three major findings. First, proET-1 and proADM levels were markedly increased at exacerbation and decreased significantly in the recovery and stable phases of the disease. Second, neither proET-1 nor proADM levels correlated consistently with the clinical presentation on hospital admission. Finally,
References (64)
- et al.
Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data
Lancet
(2006) - et al.
Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD
Chest
(2007) - et al.
Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy
Chest
(2007) - et al.
The impact of COPD on hospital resources: the specific burden of COPD patients with high rates of hospitalization
Arch Bronconeumol
(2001) - et al.
Pharmacoeconomic evaluation of COPD
Chest
(2000) - et al.
Prognostic factors in chronic obstructive pulmonary disease
Arch Bronconeumol
(2007) - et al.
Endothelin-1 induces GM-CSF, IL-6 and IL-8 but not G-CSF release from a human bronchial epithelial cell line (BEAS-2B)
Neuropeptides
(1996) - et al.
Plasma levels of adrenomedullin in primary and secondary pulmonary hypertension in patients < 20 years of age
Am J Cardiol
(1997) - et al.
Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners
J Biol Chem
(2001) - et al.
Identification of an adrenomedullin precursor fragment in plasma of sepsis patients
Peptides
(2004)
Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction
J Am Coll Cardiol
Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study
J Am Coll Cardiol
Increased plasma levels of adrenomedullin, a vasoactive peptide, in patients with end-stage pulmonary disease
Regul Pept
Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD
Chest
Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of chronic obstructive pulmonary disease
Chest
Toward a consensus definition for COPD exacerbations
Chest
Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial
Lancet
An investigation into the antimicrobial effects of adrenomedullin on members of the skin, oral, respiratory tract and gut microflora
FEMS Immunol Med Microbiol
An accelerated increase of plasma adrenomedullin in acute asthma
Metabolism
Deaths: preliminary data for 2003
Natl Vital Stat Rep
Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease
Ann Intern Med
Exacerbations of chronic obstructive pulmonary disease
Eur Respir J
Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease
Am J Respir Crit Care Med
Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease
Thorax
C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease
Am J Respir Crit Care Med
C-reactive protein levels and clinically important predictive outcomes in stable COPD patients
Eur Respir J
C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease
Thorax
Pulmonary biomarkers in chronic obstructive pulmonary disease
Am J Respir Crit Care Med
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease
Thorax
Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow
Circulation
Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?
Ann Intern Med
Endothelial cell responses to hypoxic stress
Clin Exp Pharmacol Physiol
Cited by (97)
Adrenomedullin mediates pro-angiogenic and pro-inflammatory cytokines in asthma and COPD
2019, Pulmonary Pharmacology and TherapeuticsStable-State Midrange Proadrenomedullin Is Associated With Severe Exacerbations in COPD
2018, ChestCitation Excerpt :How can we explain this finding? It is known that ADM secretion is stimulated by tumor necrosis factor-alpha, IL-beta, and lipopolysaccharide.17 Besides, hypoxia leads to ADM upregulation through the hypoxia inducible factor-1 pathway.25
What is the place for biomarkers during acute COPD exacerbations?
2017, Revue des Maladies RespiratoiresPrimary Graft Dysfunction and Mortality Following Lung Transplantation: A Role for Proadrenomedullin Plasma Levels
2016, American Journal of Transplantation
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).
- 1
Dr. Stolz was partially supported by grants from the Swiss National Foundation and the Margarete and Walter Lichtenstein Foundation.
- 2
Dr. Stolz has received speakers' honoraria from BRAHMS AG (the manufacturer of proADM, pro-endothelin, and procalcitonin assays).
- 3
Drs. Müller, Müller, and Christ-Crain served as consultants and were sponsored by BRAHMS AG for attending advisory board meetings, speaking engagements, and research.
- 4
Drs. Morgenthaler and Struck are employees of BRAHMS AG.
- 5
Drs. Christ-Cain, Miedinger, Leuppi, Bingisser, and Tamm have reported to the ACCP that no significant conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.